We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

ALCOR Scientific Inc.

ALCOR Scientific develops and manufactures proprietary devices for the clinical diagnostics and enteral feeding devic... read more Featured Products: More products

Download Mobile App




Alcor Scientific Partners with Health Care Investor Water Street to Accelerate Expansion

By LabMedica International staff writers
Posted on 01 Mar 2022
Print article
Image: Alcor Scientific Partners with Water Street (Photo courtesy of Unsplash)
Image: Alcor Scientific Partners with Water Street (Photo courtesy of Unsplash)

Alcor Scientific (Smithfield, RI, USA) has partnered with strategic health care investor Water Street Healthcare Partners (Chicago, IL, USA) which has committed significant capital to invest in Alcor's expansion.

Alcor plans to leverage Water Street's investment to achieve its goals for accelerating the development of new technologies, expanding its product portfolio and bolstering its global reach. Alcor is one of the only providers to offer a fully automated solution for Erythrocyte Sedimentation Rate (ESR) testing, which measures inflammation for a range of clinical purposes, including diagnosing and monitoring autoimmune diseases, cancer and infections. More than 1,100 hospitals and reference laboratories around the world have adopted Alcor's proprietary testing system comprised of analyzers and consumable tests. Water Street has committed significant capital to invest in Alcor's research and development initiatives, product portfolio and international expansion.

"Innovation is the cornerstone of Alcor," said Carlo Ruggeri, founder of Alcor. "Our family founded and grew this company by conceiving and developing new medical technologies that meaningfully improve patient care. I'm very pleased to have found in Water Street a strategic partner that values our legacy and will help us build on it. Water Street's diagnostics and medical products expertise combined with the experience of our new CEO, Jim Post, will help us not only build - but accelerate - Alcor's next phase of innovation and growth."

"Alcor stands out for its exceptionally high customer satisfaction and retention ratings," added Scott Garrett, operating partner at Water Street. "Health care providers greatly value Alcor's ESR testing system, saying it helps save time and labor costs to improve their overall workflow. Together with Carlo and the leadership team, we will build on this strong foundation through organic investments and acquisitions of complementary products and technologies to extend its product portfolio and global reach."

"Alcor is an outstanding company with great people who are passionate about what they do and it shows in their results," said Jim Post, Alcor’s newly-appointed CEO. "I'm excited to be joining the company at this point in its history and development and to work together to achieve our shared goal of building Alcor into a global diagnostics leader."

Related Links:
Alcor Scientific
Water Street Healthcare Partners 

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Real-time PCR System
GentierX3 Series

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: Comparison of traditional histopathology imaging vs. PARS raw data (Photo courtesy of University of Waterloo)

AI-Powered Digital Imaging System to Revolutionize Cancer Diagnosis

The process of biopsy is important for confirming the presence of cancer. In the conventional histopathology technique, tissue is excised, sliced, stained, mounted on slides, and examined under a microscope... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.